TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04584242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gluconon tab 15mg
Description: frosting and formulation : a round, convex tablet of white to gray. path of administration : once a day, two tabs, oral Amount of raw material medication (1 pill) : Pioglitazone hydrochloride 16.53mg storage method : Store 15 to 30°C to avoid light-tight containers and moisture manufacturing source : DONG-A ST

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: suganon tab 5mg
Description: frosting and formulation : pink circular film coating tablets path of administration : once a day, one tabs, oral Amount of raw material medication (1 pill) : Evogliptin tartrate 6.869mg(5mg as evogliptin) storage method : Confidential containers, stored at room temperature (1-30°C) manufacturing source : DONG-A ST
Study: NCT04150952

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HRV-based training
Description: Intervention based on HRV-guided training for the performance improvement of athletes. Pre-competitive HRV, subjective effort perception, anxiety and mood will also be analysed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TRAD training
Description: Traditional endurance training
Study: NCT01515813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin sodium
Description: Two 40mg tablets (80 mg total) of Pravastatin sodium taken orally once daily.
Study: NCT04390360

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Protective ventilation implementation
Description: In this condition, we will implement the protective ventilation related with gender and height . A blood gas will be performed at before protective ventilation implementation and at the end of this condition.Time condition 30 minutes
Study: NCT03665584

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FxCO2 Laser
Description: The FxCO2 laser allows a microablative effect in soft tissue.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Laser
Description: The Sham laser will be used on the participants who receive the sham treatment.
Study: NCT03720470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injectable Placebo
Description: Two subcutaneous injections of Placebo (for Dupilumab) administered as a loading dose on Day 1 followed by one injection every other week (q2w) until Week 16.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injectable Placebo
Description: Two subcutaneous injections of Placebo (for Dupilumab) administered as a loading dose on Day 1 followed by one injection every other week (q2w) until Week 16.
Study: NCT01003509

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: modified shouldice and double
Description: one arm modified shouldice, other one is double repair
Study: NCT01237873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ali/Amlo 150/2.5 mg
Description: Aliskiren/Amlodipine 150/2.5 mg and 150/5.0 mg
Study: NCT02794103

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Distraction
Description: VR prototype developed by the SAT will be used as the experimental intervention. It has a wide screen installed at the end of the hydrotherapy tank offering a 150-degree field view, on which appears a game allowing the child to have the immersive entertainment experience without the need to wear a helmet or 3D glasses. The child or a proxy, depending on age and burn site, will have the opportunity to interact with the game. The interactive component is not mandatory for the immersive and distractive experiences provided by the prototype. Video games tailored to the child's age and injury, different from the commercially available ones, will be adapted to each age-group of children recruited with control over the speed of movement to avoid motion sickness.
Study: NCT00854074

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ElectroCore RMS-1100 Resolution Motility System™
Description: An electrical neurostimulation signal will be applied to the spine
Study: NCT03632187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Subcutaneous abatacept every weeks during 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Subcutaneous placebo every week during 3 months
Study: NCT04059731

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition supplement
Description: Administration twice a day of Survimed OPD or Impact/Atempero depending on arm assigned during 5 postoperative days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrition supplement
Description: Administration twice a day of Survimed OPD or Impact/Atempero depending on arm assigned during 5 postoperative days
Study: NCT02608268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBG453
Description: Anti human TIM-3 monoclonal antibody. MBG453 administered via intravenous (i.v.) infusion either every 2 weeks (Q2W) or every 4 weeks (Q4W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBG453
Description: Anti human TIM-3 monoclonal antibody. MBG453 administered via intravenous (i.v.) infusion either every 2 weeks (Q2W) or every 4 weeks (Q4W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBG453
Description: Anti human TIM-3 monoclonal antibody. MBG453 administered via intravenous (i.v.) infusion either every 2 weeks (Q2W) or every 4 weeks (Q4W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBG453
Description: Anti human TIM-3 monoclonal antibody. MBG453 administered via intravenous (i.v.) infusion either every 2 weeks (Q2W) or every 4 weeks (Q4W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBG453
Description: Anti human TIM-3 monoclonal antibody. MBG453 administered via intravenous (i.v.) infusion either every 2 weeks (Q2W) or every 4 weeks (Q4W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBG453
Description: Anti human TIM-3 monoclonal antibody. MBG453 administered via intravenous (i.v.) infusion either every 2 weeks (Q2W) or every 4 weeks (Q4W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBG453
Description: Anti human TIM-3 monoclonal antibody. MBG453 administered via intravenous (i.v.) infusion either every 2 weeks (Q2W) or every 4 weeks (Q4W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBG453
Description: Anti human TIM-3 monoclonal antibody. MBG453 administered via intravenous (i.v.) infusion either every 2 weeks (Q2W) or every 4 weeks (Q4W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBG453
Description: Anti human TIM-3 monoclonal antibody. MBG453 administered via intravenous (i.v.) infusion either every 2 weeks (Q2W) or every 4 weeks (Q4W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBG453
Description: Anti human TIM-3 monoclonal antibody. MBG453 administered via intravenous (i.v.) infusion either every 2 weeks (Q2W) or every 4 weeks (Q4W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: Anti-human PD-1 monoclonal antibody. PDR001 administered via intravenous (i.v.) infusion either every 2 weeks (Q2W) or every 4 weeks (Q4W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: Anti-human PD-1 monoclonal antibody. PDR001 administered via intravenous (i.v.) infusion either every 2 weeks (Q2W) or every 4 weeks (Q4W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: Anti-human PD-1 monoclonal antibody. PDR001 administered via intravenous (i.v.) infusion either every 2 weeks (Q2W) or every 4 weeks (Q4W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: commercially available chemotherapy
Study: NCT04390360

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Protective ventilation with HME
Description: In this condition, the patient will received protective ventilation with a Heat Moisture Exchanger (HME). A blood gas will be performed at the end of this condition.Time condition 30 minutes

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Protective ventilation with Heated humidifier
Description: In this condition, the patient will received protective ventilation with a Heated humidifier. A blood gas will be performed at the end of this condition.Time condition 30 minutes
Study: NCT00745992

Intervention type: OTHER
Intervention: Blood drawn (lab data)
Description: 1. Check drug blood level 3-5 days after start of drug, treatment failure, occurence of adverse events, or clinically indicated~2. Check genetic polymorphism of liver enzyme 3-5 days after start of drug
Study: NCT00460031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoconazole
Description: 400 tid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Lenalidomide will be administered daily at a dose of 25mg po qd on days 1-21 of the cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic hydrocortisone
Description: 20mg qam 10mg qhs
Study: NCT01030523

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ASTRA TECH Implant System, OsseoSpeed™ 4.0 S (length: 6 mm)
Description: ASTRA TECH Implant System, OsseoSpeed™ 4.0 S (length: 6 mm)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ASTRA TECH Implant System, OsseoSpeed™ implants (lengths: 11, 13, 15 mm) in combination with bone grafting
Description: ASTRA TECH Implant System, OsseoSpeed™ implants (lengths: 11, 13, 15 mm) in combination with bone grafting
Study: NCT02086864

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lactose/sucrose granule (Individualized homeopathic medicine treatment)
Description: The homeopathic remedy (study medication) for each patient will be chosen from among the homeopathic medicines manufactured by Boiron Canada and currently approved for sale in Canada by Health Canada. As per classical homeopathy practice, once the most appropriate homeopathic remedy has been chosen, it will be prescribed by the homeopath according to her/his clinical judgment (maximum on a daily basis, 3 times per day, minimum 1 dose (or zero doses on the second consult or later)) with administration instructions given to the parent and patient as appropriate. Water dosing, in which a lactose/sucrose granule remedy is dissolved in 250 ml of water will be used based on the homeopath's clinical judgment. Only one remedy will be administered at a time.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo lactose/sucrose pill

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Homeopathic consultation

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Homeopathic consultation
Study: NCT02407769

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Late evening supplementation with branched chain amino acids
Description: The patients will drink a Enterex Hepatic bag (500 Kcal, 18.6g of proteins of which 8.63g are branched chain amino acids, 71.7g of carbohydrates and 15.4g of lipids) during late evening (after 19:00 hours) in comparison with the late evening snack group which will eat a snack based in food with the next nutrimental facts (480 Kcal, 19g of proteins based in casein and vegetables sources, 17g of lipids and 63g of carbohydrates) during the same schedule that intervention group.

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Late evening supplementation with branched chain amino acids
Description: The patients will drink a Enterex Hepatic bag (500 Kcal, 18.6g of proteins of which 8.63g are branched chain amino acids, 71.7g of carbohydrates and 15.4g of lipids) during late evening (after 19:00 hours) in comparison with the late evening snack group which will eat a snack based in food with the next nutrimental facts (480 Kcal, 19g of proteins based in casein and vegetables sources, 17g of lipids and 63g of carbohydrates) during the same schedule that intervention group.
Study: NCT01697865

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transfer group

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Study: NCT05717010

Intervention type: DEVICE
Intervention: Near infrared spectroscopy
Description: The Near Infrared Spectroscopy (NIRS) is the method used for monitorize the risk of the development of cerebral ischaemia while providing information about brain tissue oxygenation.

Intervention type: DEVICE
Intervention: Near infrared spectroscopy
Description: The Near Infrared Spectroscopy (NIRS) is the method used for monitorize the risk of the development of cerebral ischaemia while providing information about brain tissue oxygenation.
Study: NCT03927612

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality perspective taking training
Description: Virtual reality system provides first-person perspective of a virtual social interaction in a school cafeteria as the subject attempts to complete a goal. A virtual counterpart interferes with this goal. In the alternate perspective condition, participants will then experience the scenario again from the counterpart's perspective, including internal thoughts of the virtual counterpart.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Virtual reality control perspective
Description: Virtual reality system provides first-person perspective of a virtual social interaction in a school cafeteria as the subject attempts to complete a goal. A virtual counterpart interferes with this goal. In the control perspective condition, participants will then experience the scenario again from identical perspective.
Study: NCT04311879

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft tissue Diode laser application
Description: post-operative soft tissue diode laser application

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: mock diode laser application
Study: NCT02807350

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Overminus treatment
Description: spectacles with full cycloplegic refraction plus 2.50 D overminus added to the sphere

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-overminus treatment
Description: spectacles with full cycloplegic refraction without overminus
Study: NCT01315756

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of Few Touch Application (FTA)
Description: The users will receive a Smartphone with the diabetes diary application (the Few Touch application), a self-help tool that consists of five main elements accessible to the user. The five elements are the food habits registration, blood glucose data management system, physical activity registration, personal goals setting and general information. While blood glucose data is automatically transferred to the phone from the blood glucose meter when the user has performed a measurement, activity data and food habits have to be entered manually by the user.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of FTA and health counseling based on TTM and CBT
Description: The users will additionally receive health counseling based on TTM and CBT by a diabetes nurse with individualized feedback via SMS from the diabetes nurse which is based on the patient's initiative (via SMS). In addition, the diabetes nurse will call the patients three times during this period and discuss progress. Both the SMS-messages and the calls will be based on CBT according to the TTM-level. The intervention allows information to be given both in an individualized and tailored manner for each particular patient by the nurse, but also in a general way via SMS. The patients need to understand the relationship between areas such as glucose levels, diet, exercises and medicine, in the context of their own lifestyle needs.
Study: NCT03862274

Intervention type: OTHER
Intervention: CLN2 Treatment
Description: Patients that have a TPP1 enzyme deficiency and/or confirmed molecular diagnosis of pathogenic variants in the TPP1 gene are eligible to participate if they are receiving cerliponase alfa.
Study: NCT04390360

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tidal Volume reduction
Description: n this condition, we will reduce Tidal volume (with smartphone application calculation) to obtain the same alveolar ventilation (PaCO2) obtained on the HME condition
Study: NCT02189239

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zeller Entspannung film coated tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No Treatment
Study: NCT02027532

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Study: NCT02736487

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: True-Washout-Sham Air Filtration Intervention
Description: This intervention involved three sequential steps: (1) 12 to 20 hours of true air filtration intervention; (2) at least two weeks of washout period; (3) 12 to 20 hours of sham air filtration intervention. In the indoor environment, the portable filtration device drew room air, sent it through filter and active carbon (for true filtration) or active carbon alone (sham filtration) and then delivered processed air back to room air. In the study the portable filtration device processes 2.8 cubic meter of room air per minute. The washout period lasted for at least two weeks where no filtration intervention was implemented.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham-Washout-True Air Filtration Intervention
Description: This intervention involved three sequential steps: (1) 12 to 20 hours of sham air filtration intervention; (2) at least two weeks of washout period; (3) 12 to 20 hours of true air filtration intervention. In the indoor environment, the portable filtration device drew room air, sent it through filter and active carbon (for true filtration) or active carbon alone (sham filtration) and then delivered processed air back to room air. In the study the portable filtration device processes 2.8 cubic meter of room air per minute. The washout period lasted for at least two weeks where no filtration intervention was implemented.
Study: NCT02034786

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adipose tissue collection
Description: Only the patients selected for the Test Group will go through the procedure. The adipose tissue collection will occur in an elective surgery liposuction, in patients who meet the inclusion criteria, after signing the informed consent form. Thus, the material that would be disposed after surgery will be donated to the study.~The material for the study will be collected by the tumescent liposuction technique, which involves the removal of subcutaneous fat under local anesthesia.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Transdermal injection
Description: Transdermal injection of the filler agent composed of mesenchymal stem cells derived from autologous adipose tissue associated with hyaluronic acid.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal injection
Description: Transdermal injection of hyaluronic acid only.
Study: NCT03424265

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EAA mixture
Description: Dietary supplement intervention for 12-weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo (whey protein)
Description: Dietary supplement intervention for 12-weeks
Study: NCT02804984

Intervention type: GENETIC
Intervention: ICUS
Study: NCT02234375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: agents will be administered intravenously and a CT scan will be performed to evaluate contrast enhancement characteristics of the agents to assess their feasibility as an alternative to Iodine based contrast agents
Study: NCT01528072

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynesys Spinal System
Description: Dynesys Spinal System will be used for all subjects
Study: NCT03567837

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fructose + Glucose Beverage
Description: The intervention is an oral sugar challenge with blood sampling over three hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fructose + Glucose Beverage
Description: The intervention is an oral sugar challenge with blood sampling over three hours.
Study: NCT02106234

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No prophylactic iv hydration
Description: Control group: Patients having been referred for an elective procedure involving intravascular iodinated contrast material administration and for intravenous prophylactic hydration according to current guidelines (but only those patients with an eGFR ≥30ml/min/1.73m2) will NOT receive the standard intravenous prophylactic hydration treatment with normal saline prescribed.
Study: NCT03078621

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell Therapy
Description: Intravenous and Intrathecal transplantation of purified autologous bone marrow-derived stem cells and mesenchymal stem cells.
Study: NCT01099436

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Study: NCT00942396

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Full Field Digital Mammogram (Planmed Sophie Nuance)
Description: Full Field Digital Mammogram
Study: NCT02229318

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FruitiVits
Description: Daily administration of FruitiVits dietary supplement
Study: NCT00661076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adefovir dipivoxil
Description: 10mg po daily for 96 weeks (arm 1) or 48 weeks (arm 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adefovir dipivoxil
Description: 10mg po daily for 96 weeks (arm 1) or 48 weeks (arm 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 micrograms weekly for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 micrograms weekly for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 micrograms weekly for 48 weeks
Study: NCT02560337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel